Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Aptevo Therapeutics Inc.

Get SEC filing alerts via email and in your feed for Aptevo Therapeutics Inc.

APVO APVTW

Aptevo Therapeutics Inc.

About Aptevo Therapeutics Inc.

Aptevo Therapeutics Inc. is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer treatment. Utilizing proprietary ADAPTIR and ADAPTIR-FLEX modular protein platforms, it designs monospecific, bispecific, and multispecific antibody-based therapeutics targeting hematologic malignancies and solid tumors. Aptevo’s pipeline includes clinical and preclinical candidates that engage and modulate the immune system to enhance anti-tumor responses, serving oncology markets through innovative biologic drug development.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Aptevo Therapeutics Inc.

1
1
Aptevo Therapeutics Inc. Aptevo Therapeutics Reports $6.7 Million Net Loss in Q1 2026, Faces Funding Challenges

Via official filing (AI summary) | 22 days ago | 0 comments

2
1
Aptevo Therapeutics Inc. Aptevo Therapeutics Reports $26M Net Loss and Advances Clinical Programs in 2025

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
Aptevo Therapeutics Inc. Aptevo Therapeutics Reports $20.2 Million Net Loss and Zero Revenue for Nine Months Ended September 30, 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Aptevo Therapeutics Inc. Aptevo Therapeutics Reports $12.6 Million Net Loss, Expands Product Pipeline

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Aptevo Therapeutics Inc. Aptevo Therapeutics Reports $6.4 Million Net Loss and Decreased Operating Expenses for Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Aptevo Therapeutics Inc. Aptevo Therapeutics Reports $24.1 Million Net Loss for Fiscal Year 2024

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
Aptevo Therapeutics Inc. Aptevo Therapeutics Reports Significant Financial Challenges, Net Loss, and Cash Decline in Latest 10-Q Filing

Via official filing (AI summary) | over 1 year ago | 0 comments